Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

Trial ID or NCT#

NCT02000102

Status

not recruiting iconNOT RECRUITING

Purpose

Patients with diabetic macular edema who were switched to aflibercept after having been treated with bevacizumab or ranibizumab were retrospectively reviewed to assess for visual acuity and anatomic outcomes.

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. Those patients with diabetic macular edema switched to aflibercept from bevacizumab and/or ranibizumab -
Exclusion Criteria:
  1. None -
View All Criteria
Show Less

Investigator(s)

Theodore Leng, MD, FACS
Theodore Leng, MD, FACS
Ophthalmologist
Associate Professor of Ophthalmology and, by courtesy, of Anesthesiology, Perioperative and Pain Medicine (Adult MSD)

Contact us to find out if this trial is right for you.

Contact

Theodore Leng, MD
650-723-6995

View on ClinicalTrials.gov